Clinical Trial Update: Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and preliminary efficacy of IM19 in relapsed or refractory non-Hodgkin lymphoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• IM19

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Non Hodgkin Lymphoma | Phase 1 | Status: UNKNOWN